Keros Therapeutics, Inc. (KROS) Net margin 2019–2025
Keros Therapeutics, Inc. (KROS) net profit margin by fiscal year — reported net income divided by reported revenue.
35.7%FY2025 · since FY2019: -123.4% → 35.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 35.7% | +5313.2 pp |
| FY2024 | -5277.5% | +96041.7 pp |
| FY2023 | -101319.2% | — |
| FY2021 | -292.3% | — |
| FY2019 | -123.4% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More KROS financial trends
KROS RevenueKROS Net incomeKROS Gross profitKROS Gross marginKROS Operating incomeKROS Operating marginKROS Operating cash flowKROS Free cash flowKROS Capital expendituresKROS Return on equityKROS Stock buybacksKROS Dividends paidKROS Total assetsKROS Total liabilitiesKROS Shareholders’ equityKROS overview →